Open Access

Table IV

Data extraction describing type of study, population, intervention, control and outcomes.

Sr. no. Study, year, country Study design Population Inclusion and exclusion criteria Intervention Control/comparator group Outcome
1 Somia Iqtadar, Masooma Hashmat, et al.,
Pakistan [13]
Retrospective study 7 patients were included
Mean age-53±10years
Gender :
Males- 4
Females −3
All the patients had confirmed COVID-19 infection and typical symptoms of ROCM at the time of admission and biopsy-proven mucormycosis Group 1:
3 patients underwent surgical debridement with antifungal therapy with Amphotericin B + Posaconazole
Group 2:
4 patients underwent surgical debridement with antifungal therapy with only Amphotericin B
1 patient from Group 2 died.
The remaining 6 patients in the study survived.
2 Kyvernitakis, Torres, et al.,
2016 [10]
Retrospective study 106 patients were included
Mean age −19 to 79 yrs
Males − 69
Females- 40
Patients were eligible for inclusion if they met the European Organization for Research and Treatment of Cancer/National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group definition for invasive mucormycosis infection. Patients were excluded if they were younger than 18 years old, had solid tumours, had possible mucormycosis, had a mixed fungal infection or died within 3 days of treatment initiation Group 1: 7 patients received Posaconazole single drug therapy,
59 patients received combination of liposomal Amphotericin B + Posaconazole
Group 2:
40 patients received Liposomal Amphotericin B monotherapy
13% with monotherapy versus 15% with combination treatment died within 6 weeks
3 Jon Salmanton-Garcı́a, Danila Seidel, et al.
2019 [11]
Prospective case-control study 79 patients were included
Mean age- not mentioned
Gender − not mentioned
Patients with biopsy proven maxillary mucormycosis were included. Group 1:
5 patients received Posaconazole monotherapy,
18 patients received Amphotericin B + Posaconazole combination therapy
Group 2:
56 patients received Amphotericin B monotherapy
24 patients of Group 2 died and 6 patients of Group 1 died
4 Skiada, Pagano, et al.,
2011 [14]
Retrospective case-control study 230 cases were included in the study.
The median age of the patients was 50 years. 60% of the patients were of male gender.
The Working Group on Zygomycosis of the European Confederation of Medical Mycology (ECMM) prospectively collected cases of proven zygomycosis in 13 European countries occurring between 2005 and 2007. Group 1:
17 patients received Posaconazole monotherapy,
48 patients received Amphotericin B + Posaconazole combination therapy
Group 2:
90 patients received Amphotericin B monotherapy
19 patients in Group 1 died and 32 patients in Group 2 died.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.